

Corrigenda

Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. *BJP*, 189, 124–131. The following declarations of interest have been brought to the Editor's attention since publication of this paper: GlaxoSmithKline – speakers' bureau members: R.M.P., L.L.A., T.S.; consultants/advisory board members: R.M.P., M.A.F., W.A.N., H.G.,

S.M., P.E.K., T.S.; honoraria recipients: H.G., L.L.A.; grant recipients: M.A.F., W.A.N., P.E.K., T.S. Pfizer – speakers' bureau member: M.A.F.; consultants/advisory board members: M.A.F., W.A.N., H.G., T.S.; honoraria recipients: W.A.N., H.G.; grant recipients: M.A.F., P.E.K., T.S. Wyeth – consultants/advisory board members: M.A.F., S.M., P.E.K.;

honoraria recipients: W.A.N.; grant recipients: W.A.N., S.M., T.S.

Cognitive impairment in bipolar II disorder. *BJP*, 189, 254–259. The grant received from the Instituto Carlos III was project number FIS:PI050206.

doi: 10.1192/bjp.189.6.569